Latest News
- September 28, 2022
Dr. Lawrence Honig, professor of neurology at Columbia University Irving Medical Center, speaks about the new Alzheimer drug trial results
- July 25, 2022
"Hispanics and individuals of African ancestry have been significantly underrepresented in research of Alzheimer’s disease, although engaging underserved minorities is critical..." says Dr. Reitz
Topic
- July 5, 2022
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
- May 24, 2022
For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol, or obesity have a higher likelihood of developing Alzheimer’s disease.
Topic
- May 22, 2022
Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease.
- April 28, 2022
A recent look inside a baby zebrafish's transparent brain offers clues to how we remember and how we forget.
- April 18, 2022
Studies linked to Cassava Sciences, once a stock market favorite, have been retracted or challenged by medical journals.
- December 28, 2021
Columbia research seven years in the making highlights potential therapeutic target for neurodegenerative disease
- December 11, 2021
Various programs around the country connect neurologic patients and caregivers with the arts. One such example is Arts & Minds, an organization founded by Dr. James M. Noble
Topic
- October 26, 2021
While it may be incurable, there are several ways to treat the symptoms—and one promising but controversial new drug.
Topic
